Myocardial InfarctionNCT05793567
A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)
An observational study of Myocardial Infarction and Coronary Microvascular Disease, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction, Coronary Microvascular Disease
- What is being tested?
- Coronary angiogram with coronary reactivity testing (CRT)
- How many people
- 52 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2027to Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects receiving care at Mayo Clinic in Rochester, MN identified with T2MI and controls with atypical chest pain with indication for CMD testing will be enrolled in this study. Both groups will have no epicardial coronary stenosis >50% or obstructive disease.
Who may be able to join
- Ability to give informed consent
- Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease)
- For controls: atypical chest pain with indication for CMD testing
- For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value >99th centile+ evidence of symptoms or signs of myocardial ischemia)
Who cannot join
- Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram)
- Known to have angiographically significant CAD/pressure wire positive for epicardial CAD
- Inability to receive heparin products
- Allergy/contraindication to acetylcholine/adenosine/nitroglycerine products
- Prior coronary artery bypass grafting
- Pregnancy (if sexually active woman of reproductive age, need negative pregnancy test prior to proceeding with coronary angiography - this is standard of care in cath lab)
- Asthma with prior ICU admission due to bronchospasm/need for invasive ventilation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ischemic Heart Disease Research Team contact
United States1 site
Mayo Clinic Rochester
Rochester, Minnesota, 55905
Ischemic Heart Disease Research Team, 507-255-1724
Claire Raphael, MBBS, PhD, 507-255-2445, Raphael.Claire@mayo.edu
About this study
Official title: Assessment of Microcirculatory Function in Type 2 Myocardial Infarction
The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).
- Being tested
- Coronary angiogram with coronary reactivity testing (CRT)
- Medical subject headings
- Myocardial Infarction, Microvascular Angina
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary angiogram with coronary reactivity testing (CRT)Diagnostic test
CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
| Study group | Role | What they receive |
|---|---|---|
| T2MI Patients | Patients with T2MI and no epicardial coronary stenosis >50% will be prospectively enrolled and undergo a routine standard of care coronary angiogram with coronary reactivity testing (CRT). Receives: Diagnostic Test: Coronary angiogram with coronary reactivity testing (CRT) | |
| Controls | Patients with atypical chest pain and no obstructive disease on coronary angiogram who have been referred for investigation of suspected CMD and have a clinical indication for CMD testing will be retrospectively enrolled and data collected from a previous routine standard of care coronary angiogram with coronary reactivity testing (CRT) will be utilized. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Coronary Flow Reserve (CFR)
The CFR will be calculated as a ratio of coronary flow at peak hyperemia /coronary flow at rest.
Measured: Baseline
Secondary outcomes (1)
Backward Compression Wave (BCW)
The BCW is a measure of increased microvascular resistance during systole.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2023
- Study startJan 2027 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Claire E. Raphael, Mayo Clinic
- Investigators
- Claire Raphael, MBBS, PhD., Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05793567
- Sponsor's protocol ID
- 22-012721
- Status last verified
- Aug 2026
- First submitted
- 20 Mar 2023
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Microcirculatory Function in Type 2 Myocardial Infarction
- ClinicalTrials.gov ID
- NCT05793567
- Acronym / sponsor ID
- 22-012721
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- Jan 2027 (estimated)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 31 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| T2MI Patients | – | Diagnostic Test: Coronary angiogram with coronary reactivity testing (CRT)Patients with T2MI and no epicardial coronary stenosis >50% will be prospectively enrolled and undergo a routine standard of care coronary angiogram with coronary reactivity testing (CRT). |
| Controls | – | –Patients with atypical chest pain and no obstructive disease on coronary angiogram who have been referred for investigation of suspected CMD and have a clinical indication for CMD testing will be retrospectively enrolled and data collected from a previous routine standard of care coronary angiogram with coronary reactivity testing (CRT) will be utilized. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects receiving care at Mayo Clinic in Rochester, MN identified with T2MI and controls with atypical chest pain with indication for CMD testing will be enrolled in this study. Both groups will have no epicardial coronary stenosis >50% or obstructive disease.
Key inclusion criteria (4 listed)
- Ability to give informed consent
- Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease)
- For controls: atypical chest pain with indication for CMD testing
- For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value >99th centile+ evidence of symptoms or signs of myocardial ischemia)
Key exclusion criteria (7 listed)
- Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram)
- Known to have angiographically significant CAD/pressure wire positive for epicardial CAD
- Inability to receive heparin products
- Allergy/contraindication to acetylcholine/adenosine/nitroglycerine products
- Prior coronary artery bypass grafting
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary angiogram with coronary reactivity testing (CRT)CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol. | Diagnostic test | T2MI Patients |
Primary outcome
Coronary Flow Reserve (CFR)
Time frame: Baseline
The CFR will be calculated as a ratio of coronary flow at peak hyperemia /coronary flow at rest.
1 secondary outcome
Backward Compression Wave (BCW)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Not yet recruitingPhase 3
Cilostazol for Prevention of Recurrent Stroke Trial
Stroke Recurrence, Myocardial Infarction
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Myocardial Infarction (MI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ischemic Heart Disease Research Team contact
Claire Raphael, MBBS, PhD. principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction and Coronary Microvascular Disease, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ischemic Heart Disease Research Team (507-255-1724), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Coronary Flow Reserve (CFR) (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.